Cardiovascular and Metabolic Disorders Archive
Investigators examined the effect of progestin-only contraceptive on cardiometabolic outcomes, including stroke, MI, hypertension, diabetes, and VTE.
Fewer Major Adverse Cardiovascular Events With New Antihyperglycemic Drugs With Lower Hypoglycemic Risk
Investigators proposed that reduction in MACE may be proportional to the magnitude of HbA1c reduction seen with newer antihyperglycemic agents.
Researchers found that metabolic syndrome was associated with lower neurocognitive function, particularly among middle-aged adults.
The 1-year cardiovascular mortality hazard ratio (HR) for alendronate users was 0.33 (95% CI, 0.17 to 0.65) and 0.55 for incident myocardial infarction (95% CI, 0.34 to 0.89).
Researchers investigated effects of eplerenone on insulin sensitivity, inflammatory indices, and other metabolic parameters in HIV.
Younger patients treated with antipsychotics after experiencing a first episode of psychosis are at an increased risk for metabolic syndrome and cardiovascular disease.
In patients with asymptomatic left ventricular systolic dysfunction, diabetes is associated with an increased risk of developing heart failure.
The frequency of metabolic syndrome among patients with SLE was approximately 45%.
Findings highlight the importance of screening for metabolic syndrome (MS) and the potential for MS to influence alanine aminotransferase and its interpretation in the context of HBV treatment decisions.
Further studies are needed to assess whether beta-blockers are effective in reducing mortality and coronary events in patients with diabetes receiving optimal medical treatment.
Compared with the enalapril-treated group, those treated with sacubitril/valsartan were found to have significantly slower kidney decline.
The American Diabetes Association has updated its Clinical Standards of Medical Care guidelines for identifying and managing cardiovascular risk factors in diabetes.
Researchers examined whether menopausal symptoms, quality of life, and depression are related to arterial stiffness, a risk factor for cardiovascular disease.
Changes in serum insulin and homeostatic model assessment of insulin resistance and beta cell function were significantly greater compared to the control diet
Compared with standard care, noninvasive coronary artery disease screening reduced cardiac events by 27% in individuals with asymptomatic diabetes. Results justify larger, appropriately powered trials to potentially revisit current recommendations.
Results from the ongoing Platinum Study revealed the prevalence of risk factors for CVD among survivors of testicular cancer who received chemotherapy for their cancer.
Early treatment of cardiovascular disease risk factors such as dyslipidemia and hypertension will have long-term benefits with low risk and cost and should be more widely used in pediatric type 1 diabetes care.
Only about 50% of adults with familial hypercholesterolemia are on statin therapy, and approximately 30% of those are taking high-intensity statins.
Change in body mass index to overweight during puberty significantly increases men's risk of heart failure later in life.
Although various clinical and psychosocial factors were associated with unhealthy lifestyle factors and higher risk for CVD, the strongest associations were with negative symptoms.
Researchers examined the effect of menopausal hormone therapy on left ventricular and left atrial chamber structure and function changes, which are markers of subclinical cardiovascular disease.
Statin-associated muscle pain can hinder medication adherence which could potentially lead to an increased risk of cardiovascular events.
Researchers assessed differences in glycemic control, major cardiovascular risk factors, diabetes-related complications, sexual dysfunction prevalence, and endothelial function in young men and women with type 1 diabetes.
Statins were associated with a reduction in mortality but there was no significant difference in the composite end point with fenofibrates alone or in combination with statins.
Results provide critical perspective on cardiovascular disease associated with overweight and obesity and challenge both the obesity paradox as well as the view that overweight is associated with greater longevity.
Study found that the absence of proliferative diabetic retinopathy in those with stage 3b chronic kidney disease is associated with a lower prevalence of cardiovascular disease in patients with long duration of type 1 diabetes.
Abnormal glucose metabolism was detected in 1 out of 3 patients with nondiabetic percutaneous coronary intervention and was independently associated with a significantly higher event risk.
Study examined the association between individual antidiabetic sulfonylureas and outpatient-originating sudden cardiac arrest and ventricular arrhythmia.
Increases in waist circumference and waist-to-hip ratio are associated with a greater excess risk of myocardial infarction in women than men.
The method of individualized treatment effect prediction of fenofibrate on major cardiovascular events risk reduction in T2D can be used to guide clinical decision-making.
The acute-to-chronic glycemic ratio provided better prognostic insight with regard to in-hospital mortality and morbidity outcomes compared with glycemia levels at hospital admission in patients with diabetes who had an acute myocardial infarction.
Prior authorization requirements are greater for proprotein convertase subtilisin/kexin type 9 inhibitors than for other cardiometabolic drugs.
Abnormal ratios of omega-6 to omega-3 fatty acids were associated with the presence of bipolar disorder and the severity and duration of major depressive disorder.
A patient living near an area experiencing frequent wildfires is concerned about the potential negative effect that the wildfires may have on his health.
Patients with metabolic syndrome have a lower rate of recovery from sudden sensorineural hearing loss than those without.
The novel findings in this study suggest that patients with type 2 diabetes have a significantly reduced risk for short-term mortality after hospitalization for aortic aneurysm compared with population-based control subjects.
Abatacept conferred a greater reduction in cardiovascular risk compared with tumor necrosis factor inhibitors in patients with rheumatoid arthritis and diabetes.
A combination of selective serotonin reuptake inhibitors and antipsychotics does not lead to further deterioration of metabolic variables; however, metabolic monitoring should be performed.
ADA's recommendations reflect the latest advances in evidence-based research to improve care for millions of people with diabetes.
Duration of Prediabetes, Diabetes Independently Associated With Subclinical Atherosclerosis, Cardiac Dysfunction
Data emphasize the importance of early identification and management of those at risk for diabetes and prediabetes in order to limit exposure to the adverse cardiovascular effects of a longer duration of these conditions.
A lower bone mineral density in the lumbar spine, femoral neck, and hip is associated with an increased risk for intracranial aneurysm.
Clinical guidelines should include postpartum screening and management for all cardiovascular risk factors in women diagnosed with gestational diabetes and not restrict it to diabetes.
Weight loss after bariatric surgery in adolescents predicts the degree of longitudinal improvement in elevated high-sensitivity C-reactive protein, hyperinsulinemia, dyslipidemia, and diabetes.
New recommendations have been developed for the prevention, detection, evaluation, and management of high blood pressure.
In patients with an acute coronary syndrome and LDL-C >50 mg/dL, healthcare providers should consider adding ezetimibe to statin therapy to reduce the risk of cardiovascular events.
Only approximately half of pediatric patients with a blood pressure reading ≥95th percentile would be correctly classified based on their initial blood pressure reading.
The reduction in risk of cardiovascular death with empagliflozin is most mediated by changes in hematocrit and hemoglobin.
Patients with both gout and diabetes are at a much higher risk for stroke and myocardial infarction than with diabetes alone.
Researchers assessed the effect of both type 2 diabetes and baseline cardiovascular disease risk on the treatment effect of intensive blood pressure lowering based on data and pooled analysis from 14,094 patients.
Future studies using a renin phenotype-driven approach may efficiently identify new-onset or mild hypertension.
Risk of cardiovascular events in people with type 2 diabetes and subgroups of coronary artery disease was examined.
A life-course study evaluated the contribution of vascular endothelial dysfunction and inflammation to the development of hypertension in type 1 diabetes.
Urinary albumin-to-creatinine ratio can be independently associated with various adverse CV outcomes.
In patients with diabetes, coronary artery bypass grafting may be the preferred method of revascularization, with lower rates of major adverse cardiac or cerebrovascular events.
A study sought to clarify whether total physical activity during the day is equally as important as achieving high levels of intensity associated with moderate-to-vigorous physical activity.
Patients with diabetes taking saxagliptin, sitagliptin, second-generation sulfonylureas, pioglitazone, and long-acting insulin were assessed for the risk of acute myocardial infarction.
A strong association was found in study between poor survival in elderly patients with type 2 diabetes and cardiovascular complications, especially heart failure.
Women with hypertensive disorders during pregnancy have a significantly greater risk for future cardiovascular disease when compared with normotensive expecting mothers.
A man presents to the emergency department having had palpitations for the past week, and he has a medical history of hypertension, obesity, and hyperlipidemia. What's the diagnosis?
Cardiovascular disease hospitalization rates have declined in recent years among individuals with and those without diabetes.
Higher childhood body mass index and increases in BMI during childhood are linked to an increased risk of early adult ischemic stroke.
Despite the well‐recognized correlation between weight gain and cardiovascular (CV) disease, there is little direct evidence relating to the impact of insulin‐induced weight gain on CV outcomes.
Increased mortality risks were limited to the first post-HT year because increases in risks markedly decreased when the follow-up time was extended over more than 1 year.
Once-weekly administration of extended-release exenatide in patients with T2D at a wide range of cardiovascular risk appeared not to cause an increase in their overall cardiovascular risk.
Empagliflozin lowered the risk of cardiovascular death vs placebo when added to standard of care in adults with both type 2 diabetes and peripheral artery disease.
Levels of high sensitivity C-reactive protein may help risk stratify those patients with T2D and recent acute coronary syndrome at further risk of recurrent cardiovascular events.
Grip strength has clinical utility in identifying people with diabetes at risk for poor health outcomes.
The association between statin use and diabetes risk in a cohort of overweight and obese patients was examined.
Mepsevii replaces beta-glucuronidase, the deficiency of which causes an abnormal buildup of toxic materials in the body's cells.
Investigators encourage further research on the use of NSAIDs in women with preeclampsia who develop postpartum hypertension.
Study aimed to determine the effect of metformin on vascular health in children with T1D and above average weight.
Acarbose, an α-glucosidase inhibitor, decreased the incidence of diabetes in a population with impaired glucose tolerance who were at low risk of cardiovascular events.
People with type 2 diabetes and NOCS-NSTEMI who used incretin had a better prognosis than non-incretin users.
A study confirms whether severe hypoglycemia increases risk for all-cause mortality in patients with type 2 diabetes.
Study revealed heterogeneity in plasma glucose response to oral glucose intake beyond the established glucose criteria based on fasting plasma glucose and 2 h post-load plasma glucose levels.
Researchers assessed the impact of maternal gestational diabetes on insulin resistance and adiposity in adolescent offspring.
Studies have not previously examined long-term risks or mortality after aortic aneurysm or dissection in people with type 2 diabetes.
Study highlights the need to examine the safety of new glucose-lowering treatments specifically in patients with diabetes and heart failure and reduced ejection fraction.
Based on glycemic control and treatment method, type 2 diabetes in the heart failure population can be indicative of various risk associations.
Heart failure prevention may be an opportunity to reduce the risk of death in specific cardiovascular subcategories.
Greater prognostic advantages were associated with high-dose beta blockers in chronic heart failure with diabetes.
The latest ADA hypertension position statement incorporates advances in care since 2003.
PCSK9 inhibition with evolocumab might be an attractive therapy in patients with diabetes, and no discernible effect on glycaemia.
Patients with prediabetes who experienced intensive blood pressure management had better outcomes with CVD events and all-cause mortality.
Results suggest that medication adherence is associated with reduced risk of all-cause mortality in T2D.
BMI measurement alone can also be used to determine associations between childhood and adulthood conditions.
Increasing obesity is associated with increased ICU resource utilization in patients undergoing cardiac surgery.
From 25% to 50% of patients discontinue statins within 6 months to 1 year of starting, and the rate increases as high as 75% after 2 years.
Increases in BMI z-score between 7 and 13 years of age increase a person's risk of ischemic stroke in early adulthood.
Hyperglycemia treatment was left to physician's discretion.
The American Academy of Pediatrics released an update to previous hypertension management updates published in 2004.
Patients with MACE showed a greater extent of more severe coronary artery disease.
PCI has been linked to increased risk of CHD, mortality, MI, and repeat revascularization in type 1 diabetes.
More awareness for afib risk factors including age, severity of complications, and glycemic status are needed.
A retrospective analysis examined outcomes in patients with type 2 diabetes treated with SGLT2 vs DPP4 inhibitors.
Researchers created body size phenotypes, defined by BMI category, to assess CVD incidence in a metabolically healthy obese population.
Women with atrial fibrillation and diabetes had a higher risk for mortality and cardiovascular complications compared with men.
Losing weight may result in a decrease of heart muscle thickness.
Patients treated with zoledronic acid vs oral bisphosphonates had higher risk for heart failure and arrhythmias.
An early invasive strategy in patients with non-ST-elevation acute coronary syndromes does not necessarily reduce mortality compared with a delayed strategy.
Endocrinology Advisor Articles
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Vascular Mortality Declining in Adults With Diabetes in the United States
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- Preventing Hypoglycemia During Exercise in Type 1 Diabetes on CSII
- Implantable Continuous Glucose Monitoring Device Safe, Effective for Adolescents
- First CGM System With Implantable Glucose Sensor Approved
- Treatment for Necrobiosis Lipoidica Gets Orphan Drug Designation
- Intensified, Multifactorial Intervention for Type 2 Diabetes Reduces Risk for Heart Failure